Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H30N2.ClH |
Molecular Weight | 358.948 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCN(CC)CCCN(C1CC2=C(C1)C=CC=C2)C3=CC=CC=C3
InChI
InChIKey=KIPFVRHNAAZJOD-UHFFFAOYSA-N
InChI=1S/C22H30N2.ClH/c1-3-23(4-2)15-10-16-24(21-13-6-5-7-14-21)22-17-19-11-8-9-12-20(19)18-22;/h5-9,11-14,22H,3-4,10,15-18H2,1-2H3;1H
DescriptionSources: http://www.ndrugs.com/?s=aprindineCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/6186851
Sources: http://www.ndrugs.com/?s=aprindine
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/6186851
Aprindine is a class Ib antiarrhythmic agent. It is not approved in USA, but is available in European countries, where it is used to treat supraventricular and ventricular arrhythmias. Aprindine acts by blocking sodium voltage channels and disrupting interactions between calmodulin and prosphodiesterase.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2331043 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1660104 |
|||
Target ID: CHEMBL6093 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6186851 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | Unknown Approved UseUnknown |
|||
Primary | FIBORAN Approved UseAprindine is indicated for treatment of therapy-resistant ventricular tachycardias and ventricular extrasystoles. |
PubMed
Title | Date | PubMed |
---|---|---|
Effective plasma concentrations of aprindine in canine ventricular arrhythmias. | 1984 Jan-Feb |
|
Prediction of catalepsies induced by amiodarone, aprindine and procaine: similarity in conformation of diethylaminoethyl side chain. | 1998 Nov |
|
Theoretical possibilities for the development of novel antiarrhythmic drugs. | 2004 Jan |
|
Effect of antiarrhythmic agents on heart rate variability indices after myocardial infarction: comparative experimental study of aprindine and procainamide. | 2005 Oct |
|
Nonlinear mixed effects model analysis of the pharmacokinetics of routinely administered bepridil in Japanese patients with arrhythmias. | 2006 Mar |
|
Topics on the Na+/Ca2+ exchanger: pharmacological characterization of Na+/Ca2+ exchanger inhibitors. | 2006 Sep |
|
Pharmacological cardioversion of persistent atrial fibrillation with and without a history of drug-resistant paroxysmal atrial fibrillation. | 2006 Sep |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ndrugs.com/?s=aprindine
150-200 mg daily in divided doses, up to 300 mg/day may be used under strict observation for the first 2-3 days if needed.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1660104
Effects of aprindine (3 umol/l) on the Na+ current using whole cell voltage clamp was studied in guinea-pig ventricular myocytesd. Aprindine revealed tonic block (Kdrest = 37.7 umol/l, Kdi = 0.74 umol/l) and shifted inactivation curve to hyperpolarizing direction by 11.4+3.5 mV (n = 4) without changes in slope factor.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C47793
Created by
admin on Fri Dec 15 15:30:59 GMT 2023 , Edited by admin on Fri Dec 15 15:30:59 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DBSALT000917
Created by
admin on Fri Dec 15 15:30:59 GMT 2023 , Edited by admin on Fri Dec 15 15:30:59 GMT 2023
|
PRIMARY | |||
|
m2013
Created by
admin on Fri Dec 15 15:30:59 GMT 2023 , Edited by admin on Fri Dec 15 15:30:59 GMT 2023
|
PRIMARY | Merck Index | ||
|
33237-74-0
Created by
admin on Fri Dec 15 15:30:59 GMT 2023 , Edited by admin on Fri Dec 15 15:30:59 GMT 2023
|
PRIMARY | |||
|
DTXSID5046726
Created by
admin on Fri Dec 15 15:30:59 GMT 2023 , Edited by admin on Fri Dec 15 15:30:59 GMT 2023
|
PRIMARY | |||
|
SUB00565MIG
Created by
admin on Fri Dec 15 15:30:59 GMT 2023 , Edited by admin on Fri Dec 15 15:30:59 GMT 2023
|
PRIMARY | |||
|
71413
Created by
admin on Fri Dec 15 15:30:59 GMT 2023 , Edited by admin on Fri Dec 15 15:30:59 GMT 2023
|
PRIMARY | |||
|
236158
Created by
admin on Fri Dec 15 15:30:59 GMT 2023 , Edited by admin on Fri Dec 15 15:30:59 GMT 2023
|
PRIMARY | RxNorm | ||
|
251-418-7
Created by
admin on Fri Dec 15 15:30:59 GMT 2023 , Edited by admin on Fri Dec 15 15:30:59 GMT 2023
|
PRIMARY | |||
|
CHEMBL1213033
Created by
admin on Fri Dec 15 15:30:59 GMT 2023 , Edited by admin on Fri Dec 15 15:30:59 GMT 2023
|
PRIMARY | |||
|
PB5EKT7Q2V
Created by
admin on Fri Dec 15 15:30:59 GMT 2023 , Edited by admin on Fri Dec 15 15:30:59 GMT 2023
|
PRIMARY | |||
|
284614
Created by
admin on Fri Dec 15 15:30:59 GMT 2023 , Edited by admin on Fri Dec 15 15:30:59 GMT 2023
|
PRIMARY | |||
|
C77976
Created by
admin on Fri Dec 15 15:30:59 GMT 2023 , Edited by admin on Fri Dec 15 15:30:59 GMT 2023
|
PRIMARY | |||
|
100000085167
Created by
admin on Fri Dec 15 15:30:59 GMT 2023 , Edited by admin on Fri Dec 15 15:30:59 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD